Anika Therapeutics's major customers
DePuy Mitek accounted for 57% of Anika Therapeutics's revenue in FY 2024, about the same as 62% a year earlier.
Get an email when Anika Therapeutics's customer concentration changes
When a new annual report adds a 10% customer, drops one, or moves a share by 5 points or more, you get the change and the filing link. Up to 10 companies per address, no account, unsubscribe with one click.
Major customers of Anika Therapeutics
Customers that Anika Therapeutics named in its annual report as 10% or more of revenue. A missing year means the customer was below that line or not named.
| Customer | Share of revenue | Change vs prior year | History | Latest filing |
|---|---|---|---|---|
| DePuy Mitek | 57% | from 62% | 14 years | FY 2024 · filed 17 Mar 2025 |
Formerly disclosed
| Customer | Share of revenue | Change vs prior year | History | Latest filing |
|---|---|---|---|---|
| Boehringer | 5% | last FY 2015 | 5 years | FY 2015 · filed 10 Mar 2016 |
| Bausch And LombBLCO | 3% | last FY 2014 | 4 years | FY 2014 · filed 13 Mar 2015 |
| MedtronicMDT | 3% | last FY 2015 | 5 years | FY 2015 · filed 10 Mar 2016 |
| Rivex Pharma | 3% | last FY 2013 | 3 years | FY 2013 · filed 13 Mar 2014 |
| Nordic Pharma | 2% | last FY 2015 | 4 years | FY 2015 · filed 10 Mar 2016 |
| Pharmascience | 2% | last FY 2015 | 3 years | FY 2015 · filed 10 Mar 2016 |
About this data
US-listed companies must disclose revenue from any single customer that reaches 10% of their total (ASC 280). ShadowGraph reads these disclosures from the XBRL data of every 10-K and 20-F we scan, keeps one value per fiscal year (restatements replace earlier values) and links each number to its filing. Companies that describe a customer only as "Customer A" are not listed by name. Figures are as reported; nothing here is investment advice.
All companies · Latest dependency shifts · Bulk data and API